1[1]Thapar K, Kovacs K, Sehelthauer BW, et al. Proliferative activity and invasiveness mnong pituitary adeenonas and carcinomas: analysis using the MIB-l antibody[J]. J Neurosurg, 1996, 38:99-107
2[2]Kawamoto H, Daly MA, Mililan I, et al. Type IV collagenase activity and cavernous sinus invasion in the hunman pituitary adenoma [ J ]. Acta Neurochir, 1996, 138(4):390-340
3[3]Yildiz F, Zorlu F, Erbas T, et al. Radiotherapy in the management of giant pituitary adenomas[J]. Radiother Oncol, 1999, 52:233-237
4[4]Jho HD, Carraiu RL, Ko Y, et al. Endoscopic pituitary surgery: an early experience[J]. Surg Neurol, 1999, 47:213-222
5[5]Basaria S, Turchin A, Krasner A. Apoplexy in recurrent pituitaryadenomas[J]. Postgrad Med J, 2001, 77:23-26
6[6]Tan EU, Ho MS, Rjasoorya Cr. Metanororphosis of non-functioning pituitary adenonta to Cushing＇s disease[J]. Pituitary, 2000, 3:117-122
7[7]Machiavelli GA, Yoshimoto T, Schiwa T. Expression of c-myc and binding site: estradial and progesterone in hunan pituitary tumor[J]. Neurol Res,1998, 20:709-712
8[8]Shimom I, Pinget M, Kessler 1. Prolactinomas express human heparinbinding secretory transformation gene (hst) protein product: marker oftumor invasiveness[J]. Clin Endocrinol Oxf, 1998, 48:23
9[9]Thapar K, Schirna W, Atahaan L, et al. p53 expression in pituitarryadenoma and carcinonms: correlation with invasiveness and tumor growthfraction[J]. Neurosurgery, 1996, 38:763-769
10[10]Dickstein G. Late complication in remission from Cushing disease[J].Arch Intern Med, 1997, 10:157-161
